The Binding Properties of Glycosylated and Non- Glycosylated Tim-3 Molecules on CD4＋CD25＋ T Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: T cell immunoglobulin and mucin domain containing 3 protein (Tim-3) expressed on terminally differentiated Th1 cells plays a suppressive role in Th1-mediated immune responses. Recently, it has been shown that N-glycosylation affects the binding activity of the Tim-3-Ig fusion protein to its ligand, galectin-9, but the binding properties of non-glycosylated Tim-3 on CD4＋CD25＋ T cells has not been fully examined. In this study, we produced recombinant Tim- 3-Ig fusion proteins in different cellular sources and its N-glycosylation mutant forms to evaluate their binding activities to CD4＋CD25＋ T cells. Methods: We isolated and cloned Tim- 3 cDNA from BALB/C mouse splenocytes. Then, we constructed a mammalian expression vector and a prokaryotic expression vector for the Tim-3-Ig fusion protein. Using a site directed mutagenesis method, plasmid vectors for Tim-3-Ig N-glycosylation mutant expression were produced. The recombinant protein was purified by protein A sepharose column chromatography. The binding activity of Tim-3-Ig fusion protein to CD4＋CD25＋ T cells was analyzed using flow cytometry. Results: We found that the nonglycosylated Tim- 3-Ig fusion proteins expressed in bacteria bound to CD4＋ CD25＋ T cells similarly to the glycosylated Tim-3-Ig protein produced in CHO cells. Further, three N-glycosylation mutant forms (N53Q, N100Q, N53/100Q) of Tim-3-Ig showed similar binding activities to those of wild type glycosylated Tim-3-Ig. Conclusion: Our results suggest that N-glycosylation of Tim-3 may not affect its binding activity to ligands expressed on CD4＋CD25＋ T cells.
Abstract
Background: T cell immunoglobulin and mucin domain containing 3 protein (Tim-3) expressed on terminally differentiated Th1 cells plays a suppressive role in Th1-mediated immune responses. Recently, it has been shown that N-glycosylation affects the binding activity of the Tim-3-Ig fusion protein to its ligand, galectin-9, but the binding properties of non-glycosylated Tim-3 on CD4＋CD25＋ T cells has not been fully examined. In this study, we produced recombinant Tim- 3-Ig fusion proteins in different cellular sources and its N-glycosylation mutant forms to evaluate their binding activities to CD4＋CD25＋ T cells. Methods: We isolated and cloned Tim- 3 cDNA from BALB/C mouse splenocytes. Then, we constructed a mammalian expression vector and a prokaryotic expression vector for the Tim-3-Ig fusion protein. Using a site directed mutagenesis method, plasmid vectors for Tim-3-Ig N-glycosylation mutant expression were produced. The recombinant protein was purified by protein A sepharose column chromatography. The binding activity of Tim-3-Ig fusion protein to CD4＋CD25＋ T cells was analyzed using flow cytometry. Results: We found that the nonglycosylated Tim- 3-Ig fusion proteins expressed in bacteria bound to CD4＋ CD25＋ T cells similarly to the glycosylated Tim-3-Ig protein produced in CHO cells. Further, three N-glycosylation mutant forms (N53Q, N100Q, N53/100Q) of Tim-3-Ig showed similar binding activities to those of wild type glycosylated Tim-3-Ig. Conclusion: Our results suggest that N-glycosylation of Tim-3 may not affect its binding activity to ligands expressed on CD4＋CD25＋ T cells.
참고문헌 (11)
- Monney L, "Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease", Nature, 415, pp.536~541 (2002)
- Sabatos CA, "Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance", Nat Immunol, 4, pp.1102~1110 (2003)
- Wiener Z, "TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells", J Invest Dermatol, 127, pp.906~914 (2007)
- Kuchroo VK, "TIM family of genes in immunity and tolerance", Adv Immunol, 91, pp.227~249 (2006)
- Sanchez-Fueyo A, "Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance", Nat Immunol, 4, pp.1093~1101 (2003)
- Frisancho-Kiss S, "T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity", J Immunol, 176, pp.6411~6415 (2006)
- Oikawa T, "Preferential involvement of Tim-3 in the regulation of hepatic CD8+ T cells in murine acute graft-versus-host disease", J Immunol, 177, pp.4281~4287 (2006)
- Zhu C, "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity", Nat Immunol, 6, pp.1245~1252 (2005)
- Medzihradszky KF, "Characterization of site-specific N-glycosylation", Methods Mol Biol, 446, pp.293~316 (2008)
- Cao E, "T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface", Immunity, 26, pp.311~321 (2007)
- Seki M, "Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis", Clin Immunol, 127, pp.78~88 (2008)